Analysts think BPMC stock price could increase by 65%
Apr 06, 2025, 11:25 AM
24.61%
What does BPMC do
Blueprint Medicines, headquartered in Cambridge, Massachusetts, develops precision therapies for cancer and blood disorders, employing 645 fulltime staff. It has approved medicines like AYVAKIT and GAVRETO, with ongoing research in various cancers.
24 analysts think BPMC stock price will increase by 64.80%. The current median analyst target is $134.64 compared to a current stock price of $81.70. The lowest analysts target is $83.83 and the highest analyst target is $177.45.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
